Source: Annual Congress 2006 - Lung transplantation: clinical issues



Rating:

Share or cite this content

Citations should be made in the following way:
M. Hofer, R. Speich, F. Wick, W. Weder, A. Boehler (Zurich, Switzerland). Mycophenolate mofetil reduces alveolar inflammation and acute rejection and improves overall outcome after lung transplantation. Eur Respir J 2006; 28: Suppl. 50, 4154

Member's Comments

No comment yet.

Related content which might interest you: Impact of mycophenolate mofetil on lung function in chronic hypersensitivity pneumonitis and connective tissue disease related-ILD Source: Virtual Congress 2020 – Natural history and management of interstitial lung diseases of known cause Year: 2020 Safety and effectiveness of mycophenolate mofetil in interstitial lung diseases Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Mycophenolate mofetil (MMF) rescue therapy in lung transplantation: results and pharmacokinetics Source: Eur Respir J 2002; 20: Suppl. 38, 348s Year: 2002 Results of switch from mycophenolate mofetil to azathioprin after lung transplantation Source: Eur Respir J 2004; 24: Suppl. 48, 178s Year: 2004 Basiliximab induction reduces the incidence of acute rejection in lung transplant patients Source: International Congress 2018 – Moving lung transplantation forward Year: 2018 Mycophenolate mofetil and azathioprine in chronic hypersensitivity pneumonitis Source: International Congress 2016 – Orphan diseases I Year: 2016 Efficacy of tacrolimus rescue therapy in refractory acute rejection (AR) after lung transplantation Source: Eur Respir J 2001; 18: Suppl. 33, 298s Year: 2001 Can mycophenolate mofetil 15 mg/kg/day attenuate experimental pulmonary fibrosis in rats? Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis Year: 2009 Pulmonary alveolar proteinosis due to mycophenolate and cyclosporine combination therapy in a renal transplant recipient Source: Annual Congress 2012 - Respiratory manifestations of systemic disease: a holistic approach Year: 2012 A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation Source: Eur Respir J 2011; 37: 164-172 Year: 2011 Aerosolized liposomal cyclosporine A for treatment of progressive allograft dysfunction following lung transplantation Source: Annual Congress 2013 –Clinical studies in lung transplantation Year: 2013 Early sirolimus immunosuppression is safe in lung transplantation Source: Annual Congress 2012 - Optimising outcomes after lung transplantation Year: 2012 A model of chronic lung allograft rejection in the rat Source: Eur Respir J 2010; 35: 1354-1363 Year: 2010 A case series on the use of steroids and mycophenolate mofetil in idiopathic and heritable pulmonary veno-occlusive disease: is there a role for immunosuppression? Source: Eur Respir J, 57 (6) 2004354; 10.1183/13993003.04354-2020 Year: 2021 The intervening effects of mycophenolate mofetil on CD34+ hematopoietic cells in bone marrow of asthma mice Source: Eur Respir J 2005; 26: Suppl. 49, 137s Year: 2005 Aerosol cyclosporin therapy in lung transplant recipients with bronchiolitis obliterans Source: Eur Respir J 2004; 23: 384-390 Year: 2004 Immunosuppressive therapy after human lung transplantation Source: Eur Respir J 2004; 23: 159-171 Year: 2004 Pathophysiology of the lung allograft: pathways of graft rejection Source: Annual Congress 2005 - PG9 - Long-term follow-up of lung transplant recipients Year: 2005 Evaluation of lung mechanics and the progression of disease in acute allograft rejection after lung transplantation Source: Annual Congress 2010 - New clinical and experimental insights in lung transplantation Year: 2010 Immunosuppressive therapy after human lung transplantation Source: ISSN=1025-448x, ISBN=1-904097-29-4, page=105 Year: 2003